SCHEMBL1109382

SCHEMBL1109382

NC[C@H](NC(=O)c1ccc(-c2ccc(NC(=O)CN3CCN(c4ccc(F)cc4)CC3)cc2)cc1)C(=O)NO

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.56
▸ HTT P42858 2/20 0.56
▸ MAPT P10636 2/20 0.56
▸ REV1 Q9UBZ9 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ GAA P10253 2/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ ALOX12 P18054 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.49
▸ RXFP1 Q9HBX9 1/20 0.48
▸ DRD4 P21917 1/20 0.48
▸ TSHR P16473 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400947 0.92 LMNA (0.53) LMNAHTTMAPTREV1CA12
SCHEMBL1912247 0.91 GAA (0.59) LMNAHTTMAPTREV1CA12
SCHEMBL1109235 0.86 ALDH1A1 (0.55) LMNAHTTMAPTREV1MEN1
SCHEMBL1109491 0.86 NPC1 (0.52) LMNAHTTMAPTMEN1KMT2A
SCHEMBL1109311 0.85 GAA (0.47) LMNAMEN1KMT2AGAAALOX15
SCHEMBL1109173 0.85 ATM (0.51) LMNACA1CA2ALOX15TDP1
SCHEMBL1109391 0.85 ATM (0.51) LMNACA1CA2ALOX15TDP1
SCHEMBL1109178 0.85 REV1 (0.56) LMNAHTTMAPTREV1CA12
SCHEMBL1109140 0.85 NPC1 (0.51) HTTMAPTMEN1KMT2AGAA
SCHEMBL1109363 0.85 NPC1 (0.51) HTTMAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153843-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2012-04-10 — — US disclosed
US-8101640-B2 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-01-24 — — US disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 — — US disclosed
US-7989660-B2 BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2011-08-02 — — US disclosed
US-20110172174-A1 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS INC. 2011-07-14 — — US disclosed
US-20100324025-A1 Antibacterial Agents UNIVERSITY OF WASHINGTON (US) 2010-12-23 — — US disclosed
US-20090163496-A1 ANTIBACTERIAL AGENTS UNIVERSITY OF WASHINGTON (US) 2009-06-25 — — US disclosed
US-20080269221-A1 ANTIBACTERIAL AGENTS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-10-30 — — US disclosed
US-7358359-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2008-04-15 — — US disclosed
US-20070244197-A1 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2007-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244197-A1 Antibacterial agents MRPL21, SI, PGLS LMNA 3397/4885HTT 4781/4885MAPT 4619/4885
US-20110172174-A1 Antibacterial agents MRPL21, SI, PGLS LMNA 3397/4885HTT 4781/4885MAPT 4619/4885
US-20080269221-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS LMNA 3397/4885HTT 4781/4885MAPT 4619/4885
US-20090163496-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS LMNA 3397/4885HTT 4781/4885MAPT 4619/4885
US-20100324025-A1 Antibacterial Agents MRPL21, SI, PGLS LMNA 3397/4885HTT 4781/4885MAPT 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback